Akèy › Limfom selil mantèl › North Carolina › Durham
Etid klinik pou Limfom selil mantèl nan Durham, NC
13 etid pou Limfom selil mantèl ap chèche patisipan nan sit nan ak bò kote Durham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Ap rekriteFaz 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Ap rekriteFaz 3
- Duke University, Durham
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill · 10 mi lwen
DALY II USA/ MB-CART2019.1 for DLBCL
Ap rekriteFaz 2
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- Duke University Medical Center, Durham
Registry of Older Patients With Cancer
Ap rekriteEtid obsèvasyon
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi lwen
Study of SGR-1505 in Mature B-Cell Neoplasms
Ap rekriteFaz 1
- Duke University, Durham
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Ap rekriteFaz 1
- Duke Univerisity, Durham
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Ap rekriteFaz 1
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi lwen
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- Duke University, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi lwen
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Ap rekriteEtid obsèvasyon
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi lwen
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Ap rekriteFaz 1
- University of North Carolina, Chapel Hill · 10 mi lwen
Etid Limfom selil mantèl nan lòt vil
- Baldwin Park, CA15 etid
- Houston, TX15 etid
- New York City, NY12 etid
- Milwaukee, WI12 etid
- Seattle, WA12 etid
- Boston, MA11 etid
- Columbus, OH11 etid
- Nashville, TN11 etid
- Chicago, IL10 etid
- Portland, OR9 etid
- Rochester, MN9 etid
- St. Louis, MO8 etid
Lòt etid nan Durham
- Kansè nan tete63 etid
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil39 etid
- Myelom Miltip37 etid
- Kansè Metastatik33 etid
- Leksemi mieloïd egi33 etid
- Kansè poumon32 etid
- Kansè pwostat32 etid
- Kansè kolorektal28 etid
- Lukemi lenfositè kwonik27 etid
- Kansè ovè27 etid
- Ensifizyans kadyak26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.